About trametinib dimethylsulfoxide
MEK inhibitor anticancer medicine
Used for
- Treats certain BRAF-mutated cancers, including melanoma and lung cancer.
- Used alone or with dabrafenib for selected cancers, depending on tumor type and treatment history.
Usual adult dose
Usually 2 mg by mouth once daily; dosing depends on the cancer and combination treatment.
Usual dose in children
For certain cancers in children, dose is based on body size and taken once daily; specialist-directed.
Common side effects
- Rash, diarrhea, nausea, or vomiting
- Swelling, tiredness, or fever
- Heart function problems
- Eye problems or lung inflammation
Important warnings
- Can cause serious heart, eye, or lung problems; monitoring is required.
- May cause severe skin reactions, bleeding, or blood clots.
- Can harm an unborn baby; pregnancy testing and effective contraception are important.
- Do not substitute for or combine with another trametinib product without specialist guidance.
Pregnancy
May cause fetal harm. Avoid pregnancy during treatment and for 4 months after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment or for 4 months after the last dose.
Interactions
- Some medicines can alter trametinib exposure; provide the care team with a complete medication list.
- Taking dabrafenib with trametinib changes the treatment’s benefits and risks.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.